Ficlatuzumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | HGF |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6446H9954N1718O2026S46 |
Molar mass | 145409.30 g·mol−1 |
NY (what is this?) (verify) |
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[2]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
- ↑ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012
Growth factor receptor modulators | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Angiopoietin |
| ||||||||||
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) | |||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.